Relation between systemic hypertension and blood lipids on the risk of myocardial infarction

被引:23
作者
Gaziano, JM
Sesso, HD
Breslow, JL
Hennekens, CH
Buring, JE
机构
[1] Harvard Univ, Vet Affairs Med Ctr, Massachusetts Vet Epidemiol Res & Infomat Ctr, Brockton, MA 02401 USA
[2] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[5] Rockefeller Univ, Biochem Genet & Metab Lab, New York, NY 10021 USA
[6] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA
关键词
D O I
10.1016/S0002-9149(99)00435-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We sought to evaluate the potential interactions between systemic hypertension and blood lipids on the risk of myocarclial infarction (MI). Recent evidence suggests that hypertension may interact with other risk factors such as dyslipidemia in the development of coronary heart disease. However, the precise nature of that interrelation remains unclear. We selected 340 cases of first MI and an equal number of age-, sex-, and community-matched controls, Data were collected on a large number of coronary risk factors, and fasting blood samples were obtained. Logistic regression was used to calculate the odds ratio (OR) of nonfatal MI. The age- and sex-adjusted OR of MI was 1.61 (95% confidence interval [CI] 1.15 to 2.25) among treated hypertensives compared with nonhypertensives, Further adjustment for coronary risk factors did not materially alter the results (OR 1.67, 95% CI 1.16 to 2.41), To explore the interrelations among hypertension, lipids, and risk of MI, each lipoprotein parameter was individually added to the risk factor-adjusted multivariate model. The apparent risk associated with hypertension was substantially attenuated by the addition of either high-density lipoprotein cholesterol (OR 1.25, 95% CI 0.82 to 1.90) or triglycerides (OR 1.37, 95% CI 0.91 to 2.05), No significant interactions were found between hypertension and any lipoprotein parameter. These data indicate that the risk of MI associated with treated hypertension may have a lipid mechanism involving high-density lipoprotein cholesterol and/or triglycerides, (C) 1999 by Excerpta Medico, Inc.
引用
收藏
页码:768 / 773
页数:6
相关论文
共 31 条
[1]  
[Anonymous], 1982, CASE CONTROL STUDIES
[2]   DECREASED HDL2 AND HDL3 CHOLESTEROL, APO A-I AND APO A-II, AND INCREASED RISK OF MYOCARDIAL-INFARCTION [J].
BURING, JE ;
OCONNOR, GT ;
GOLDHABER, SZ ;
ROSNER, B ;
HERBERT, PN ;
BLUM, CB ;
BRESLOW, JL ;
HENNEKENS, CH .
CIRCULATION, 1992, 85 (01) :22-29
[3]   BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT [J].
COLLINS, R ;
PETO, R ;
MACMAHON, S ;
HEBERT, P ;
FIEBACH, NH ;
EBERLEIN, KA ;
GODWIN, J ;
QIZILBASH, N ;
TAYLOR, JO ;
HENNEKENS, CH .
LANCET, 1990, 335 (8693) :827-838
[4]   PLASMA TRIGLYCERIDE LEVEL AND MORTALITY FROM CORONARY HEART-DISEASE [J].
CRIQUI, MH ;
HEISS, G ;
COHN, R ;
COWAN, LD ;
SUCHINDRAN, CM ;
BANGDIWALA, S ;
KRITCHEVSKY, S ;
JACOBS, DR ;
OGRADY, HK ;
DAVIS, CE .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (17) :1220-1225
[5]  
FERANNINI E, 1987, NEW ENGL J MED, V317, P350
[6]  
FYFE T, 1971, LANCET, V2, P997
[7]  
GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810
[8]   VALIDITY OF SERUM TOTAL CHOLESTEROL LEVEL OBTAINED WITHIN 24 HOURS OF ACUTE MYOCARDIAL-INFARCTION [J].
GORE, JM ;
GOLDBERG, RJ ;
MATSUMOTO, AS ;
CASTELLI, WP ;
MCNAMARA, PM ;
DALEN, JE .
AMERICAN JOURNAL OF CARDIOLOGY, 1984, 54 (07) :722-725
[9]   RELATIONSHIP OF PSYCHOSOCIAL FACTORS TO CORONARY HEART-DISEASE IN FRAMINGHAM STUDY .1. METHODS AND RISK-FACTORS [J].
HAYNES, SG ;
LEVINE, S ;
SCOTCH, N ;
FEINLEIB, M ;
KANNEL, WB .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1978, 107 (05) :362-383
[10]   DOES LOWERING OF CHOLESTEROL LEVELS INFLUENCE FUNCTIONAL-PROPERTIES OF LARGE ARTERIES [J].
KOOL, M ;
LUSTERMANS, F ;
KRAGTEN, H ;
BOUDIER, HS ;
HOEKS, A ;
RENEMAN, R ;
RILA, H ;
HOOGENDAM, I ;
VANBORTEL, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 48 (3-4) :217-223